Nuvectis Pharma (NASDAQ: NVCT) awards 150,000 restricted shares

Rhea-AI Filing Summary

Nuvectis Pharma, Inc. reported an equity grant to a senior officer. Chief Science & Business Officer Enrique Poradosu received 150,000 shares of restricted common stock on January 6, 2026, at a stated price of $0 per share, reflecting a compensatory award rather than an open-market purchase.

The 150,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, and are conditioned on Mr. Poradosu’s continued service on each vesting date. Following this grant, he beneficially owned 1,806,319 shares of Nuvectis common stock, which includes restricted shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Poradosu Enrique

Role Chief Science & Business Off

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	150,000	$0.00	--

Holdings After Transaction: Common Stock — 1,806,319 shares (Direct)

Footnotes (1)

1. The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates. Includes shares of restricted common stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poradosu Enrique

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NJ 07024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science & Business Off

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		150,000(1)	A	$0	1,806,319(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates.

2. Includes shares of restricted common stock.

	/s/ Enrique Poradosu	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuvectis Pharma (NVCT) disclose?

Nuvectis Pharma disclosed that Chief Science & Business Officer Enrique Poradosu was granted 150,000 shares of restricted common stock on January 6, 2026.

Was the Nuvectis Pharma (NVCT) insider grant a market purchase or a compensation award?

The Form 4 shows transaction code A and a price of $0 per share, indicating the 150,000 shares were awarded as equity compensation, not bought in the market.

What is the vesting schedule for the 150,000 restricted Nuvectis (NVCT) shares?

The 150,000 restricted shares will vest in equal annual installments over three years, starting on the first anniversary of the grant date, subject to Mr. Poradosu’s continued service.

How many Nuvectis Pharma (NVCT) shares does Enrique Poradosu own after this transaction?

After the grant, Enrique Poradosu beneficially owned 1,806,319 shares of Nuvectis common stock, including restricted shares.

Is Enrique Poradosu’s ownership in Nuvectis (NVCT) direct or indirect?

The Form 4 reports Mr. Poradosu’s 1,806,319 shares as held with direct ownership, with no separate indirect ownership entity noted.

What is Enrique Poradosu’s role at Nuvectis Pharma (NVCT)?

Enrique Poradosu is an officer of Nuvectis Pharma, serving as Chief Science & Business Officer, according to the filing.